ZLAB Logo

Zai Lab Limited (ZLAB) 

NASDAQ
Market Cap
$2.93B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
277 of 959
Rank in Industry
166 of 550

Largest Insider Buys in Sector

ZLAB Stock Price History Chart

ZLAB Stock Performance

About Zai Lab Limited

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular …

Insider Activity of Zai Lab Limited

Over the last 12 months, insiders at Zai Lab Limited have bought $126,690 and sold $2.92M worth of Zai Lab Limited stock.

On average, over the past 5 years, insiders at Zai Lab Limited have bought $222,127 and sold $60.45M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Smiley Joshua L (See Remarks) — $253,380.

The last purchase of 3,000 shares for transaction amount of $64,200 was made by Smiley Joshua L (See Remarks) on 2024‑05‑13.

List of Insider Buy and Sell Transactions, Zai Lab Limited

2024-11-04SaleChief Financial Officer
167
0.0002%
$30.66$5,121-9.40%
2024-10-02SaleChief Financial Officer
301
0.0003%
$25.40$7,645+7.46%
2024-09-03Saledirector
2,500
0.0025%
$19.50$48,750+36.23%
2024-08-19SaleChief Legal Officer
1,924
0.0019%
$16.95$32,620+54.09%
2024-08-16SaleSee Remarks
4,352
0.0045%
$16.67$72,561+1.90%
2024-08-15SaleChief Financial Officer
422
0.0004%
$16.06$6,7790.00%
2024-08-12SaleSee Remarks
3,115
0.0031%
$16.20$50,463+60.88%
2024-07-01SaleChairperson & CEO
7,013
0.0069%
$17.48$122,5730.00%
2024-07-01Saledirector
10,397
0.0102%
$17.32$180,0850.00%
2024-06-26SaleChairperson & CEO
23,939
0.0242%
$17.90$428,532+37.76%
2024-06-26SaleSee Remarks
7,431
0.0075%
$17.90$133,022+37.76%
2024-06-26SaleChief Legal Officer
5,062
0.0051%
$17.90$90,615+37.76%
2024-06-26SaleChief Financial Officer
2,154
0.0022%
$17.90$38,559+37.76%
2024-05-14SaleChief Legal Officer
10,000
0.01%
$21.33$213,346-4.87%
2024-05-13PurchaseSee Remarks
3,000
0.003%
$21.40$64,200-4.46%
2024-04-04SaleSee Remarks
2,105
0.0022%
$15.67$32,992+29.00%
2024-04-04SaleSee Remarks
1,988
0.002%
$15.67$31,158+29.00%
2024-04-04SaleChief Legal Officer
1,244
0.0013%
$15.67$19,497+29.00%
2024-04-04SaleSee Remarks
1,952
0.002%
$15.67$30,594+29.00%
2024-04-04SaleChief Financial Officer
845
0.0009%
$15.67$13,244+29.00%

Insider Historical Profitability

<0.0001%
Smiley Joshua LSee Remarks
43232
0.0397%
$26.8942
WIRTH PETERdirector
0
0%
$26.8911<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Wellington Management Company$106.66M6.686.66M+24.76%+$21.17M0.02
Capital World Investors$91.06M5.715.68M+8.92%+$7.45M0.02
Janus Henderson$70.92M4.454.43M+9.6%+$6.21M0.04
Woodline Partners LP$41.6M2.612.6M+28.65%+$9.26M0.36
Viking Global Investors$32.81M2.062.05M+9.57%+$2.87M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.